ストックスクリーナーアプリを入手
6.07
8.90%
0.45
アフターアワーズ：
6.07
前日終値:
$5.62
開ける：
$5.58
24時間の取引高:
133.53K
Relative Volume:
1.15
時価総額：
$46.28M
収益：
$140.46M
当期純損益:
$-146.34M
株価収益率:
-4.7795
EPS:
-1.27
ネットキャッシュフロー:
$-117.73M
1週間 パフォーマンス:
+13.33%
1か月 パフォーマンス:
+47.12%
6か月 パフォーマンス:
-54.67%
1年 パフォーマンス:
-61.51%
1日の値動き範囲:
$5.5193
$6.32
1週間の範囲:
$5.39
$6.56
52週間の値動き範囲:
$3.51
$18.00
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
KPTI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.07 | 46.28M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Medidata Solutions, Inc. Announces Expanded Partnership with Karyopharm Therapeutics - marketscreener.com
Karyopharm therapeutics CEO Richard Paulson sells $916 in stock By Investing.com - Investing.com South Africa
Karyopharm therapeutics CEO Richard Paulson sells $916 in stock - Investing.com
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
KPTI stock touches 52-week low at $5.55 amid market challenges - Investing.com
Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com
Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Executives Sell Shares - TradingView
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com
Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com
Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat
FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm announces 1-for-15 reverse stock split - MSN
Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia
Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa
Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com
Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq
Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com
Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune
Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
0.63%
大文字化:
|
ボリューム (24 時間):